MUCOR-ADVANCE: Better Diagnosis and Care for Mucormycosis in High-Risk Patients
Official title: Clinical Core
Funded at Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center · NIH-11364080 · Data updated 2026-11-12
A multi-center project aims to improve how mucormycosis is diagnosed and managed in people with weakened immune systems by collecting patient samples and clinical data to guide risk-based care.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center NIH-funded |
| Lab location | 1 site (Torrance, United States) |
| Project start | July 1, 2025 |
| Project end | May 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $229,233 |
| NIH project number | 5P01AI186818-02 |
| Project ID | NIH-11364080 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults (21+ years) at high risk for mucormycosis or with confirmed MCM, including those with invasive aspergillosis, bacterial pneumonia, or on mold-active antifungal prophylaxis.
✕Less likely to help
Patients without mucormycosis or those not enrolled in high-risk settings may not directly benefit from this core.
What this research studies
This program will collect fungal and patient biospecimens from people with mucormycosis and comparison groups, along with detailed clinical information, to build a richer picture of the disease. It will explore new biomarkers and diagnostic approaches, plus adjunctive therapies that target the patient or the pathogen. The Clinical Core at a major cancer center will coordinate prospective sample collection and data integration to support risk stratification and personalized management. The effort will help clinicians act faster and tailor treatments for those at highest risk of poor outcomes.
Why it matters
Potential benefit: If successful, patients with mucormycosis could receive earlier, more accurate diagnoses and personalized treatment plans to improve survival and recovery.
How similar studies have gone: Previous work has shown that combining biomarkers with clinical data can improve risk stratification in fungal infections; this project builds on that approach.
Where this research is happening
-
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Torrance, United States Active
Researchers
- Principal investigator: Kontoyiannis, Dimitrios P — Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
- Study coordinator: Kontoyiannis, Dimitrios P
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.